These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 27323543)

  • 41. A Global Approach to Rare Diseases Research and Orphan Products Development: The International Rare Diseases Research Consortium (IRDiRC).
    Cutillo CM; Austin CP; Groft SC
    Adv Exp Med Biol; 2017; 1031():349-369. PubMed ID: 29214582
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Rare diseases: what's next?
    Remuzzi G; Garattini S
    Lancet; 2008 Jun; 371(9629):1978-9. PubMed ID: 18555899
    [No Abstract]   [Full Text] [Related]  

  • 43. Perspectives for improving the evaluation and access of therapies for rare lung diseases in Europe.
    Luisetti M; Balfour-Lynn IM; Johnson SR; Miravitlles M; Strange C; Trapnell BC; van Bronswijk H; Vogelmeier C
    Respir Med; 2012 Jun; 106(6):759-68. PubMed ID: 22414566
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Issues surrounding orphan disease and orphan drug policies in Europe.
    Denis A; Mergaert L; Fostier C; Cleemput I; Simoens S
    Appl Health Econ Health Policy; 2010; 8(5):343-50. PubMed ID: 20804226
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [The situation of rare skin diseases in Germany].
    Bruckner-Tuderman L; Traupe H; Krieg T
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2007 Dec; 50(12):1541-7. PubMed ID: 18026883
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Intractable and rare diseases research in Asia.
    Song P; Gao J; Inagaki Y; Kokudo N; Tang W
    Biosci Trends; 2012 Apr; 6(2):48-51. PubMed ID: 22621985
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [The national plan for orphan rare diseases: nearly 10 years on].
    Guillevin L
    Rev Neurol (Paris); 2013 Feb; 169 Suppl 1():S9-11. PubMed ID: 23452775
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Orphan diseases: what are the roles for associations? ].
    Araiedh J; Badoux T; Berweiler A; Egli L; Gartmann M
    Rev Med Suisse; 2013 Jul; 9(393):1435-6. PubMed ID: 23971330
    [No Abstract]   [Full Text] [Related]  

  • 49. Focus on designing health care structures and services for rare diseases.
    Schultz C; Schreyögg J; Stargardt T; Busse R
    Health Policy; 2012 May; 105(2-3):107-9. PubMed ID: 22469233
    [No Abstract]   [Full Text] [Related]  

  • 50. [Skeletal dysplasias. The network SKELNET].
    Després S; Engel MW; Zabel B
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2007 Dec; 50(12):1548-55. PubMed ID: 18026882
    [TBL] [Abstract][Full Text] [Related]  

  • 51. How Doctors Think: Common Diagnostic Errors in Clinical Judgment-Lessons from an Undiagnosed and Rare Disease Program.
    Kliegman RM; Bordini BJ; Basel D; Nocton JJ
    Pediatr Clin North Am; 2017 Feb; 64(1):1-15. PubMed ID: 27894438
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Orphanet: a European database for rare diseases].
    Weinreich SS; Mangon R; Sikkens JJ; Teeuw ME; Cornel MC
    Ned Tijdschr Geneeskd; 2008 Mar; 152(9):518-9. PubMed ID: 18389888
    [TBL] [Abstract][Full Text] [Related]  

  • 53. General knowledge and awareness on rare diseases among general practitioners in Bulgaria.
    Miteva Ts; Jordanova R; Iskrov G; Stefanov R
    Georgian Med News; 2011 Apr; (193):16-9. PubMed ID: 21617267
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Rare diseases with renal involvement in the Republic of Macedonia.
    Tasic V; Lozanovski VJ; Danilovski D; Laban N; Pop-Jordanova N; Polenakovic M; Gucev ZS
    Prilozi; 2011; 32(1):55-67. PubMed ID: 21822178
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A cross-national comparative study of orphan drug policies in the United States, the European Union, and Japan: towards a made-in-China orphan drug policy.
    Liu BC; He L; He G; He Y
    J Public Health Policy; 2010 Dec; 31(4):407-20; discussion 420-1. PubMed ID: 21119648
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Rare bleeding disorders in children: identification and primary care management.
    Acharya SS
    Pediatrics; 2013 Nov; 132(5):882-92. PubMed ID: 24127475
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Personalized medicine from the viewpoint of patients and their relatives].
    Pogány G
    Magy Onkol; 2013 Mar; 57(1):11-5. PubMed ID: 23573516
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The Orphan Drug Act and the development of stem cell-based products for rare diseases.
    Freeman SN; Burke KA; Imoisili MA; Coté TR
    Cell Stem Cell; 2010 Sep; 7(3):283-7. PubMed ID: 20804965
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Translation of rare disease research into orphan drug development: disease matters.
    Heemstra HE; van Weely S; Büller HA; Leufkens HG; de Vrueh RL
    Drug Discov Today; 2009 Dec; 14(23-24):1166-73. PubMed ID: 19818412
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Call for a national plan for rare diseases.
    Jaffe A; Zurynski Y; Beville L; Elliott E
    J Paediatr Child Health; 2010 Jan; 46(1-2):2-4. PubMed ID: 19943870
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.